Specifically, mice treatment with low doses of anti-VEGFR2 antibodies not only normalizes tumor vessels but also results in more robust immune cell infiltration, thus providing important insights into the optimal strategies for combining immunotherapy with molecular-targeted agents [134]. The gene discussed is KDR; the disease is neoplasm.